Royal Bank Of Canada Akouos, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.6 - $5.16 $166 - $330	64 Added 64.0%	164 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.46 - $5.2 $3,628 - $7,670	-1,475 Reduced 93.65%	100 $0
Q1 2022 May 16, 2022	SELL	$4.16 - $9.08 $13,952 - $30,454	-3,354 Reduced 68.05%	1,575 $7,000
Q4 2021 Feb 14, 2022	BUY	$7.65 - $11.38 $9,937 - $14,782	1,299 Added 35.79%	4,929 $42,000
Q3 2021 Nov 15, 2021	BUY	$9.93 - $13.59 $18,678 - $25,562	1,881 Added 107.55%	3,630 $42,000

Q2 2021 Aug 16, 2021	BUY	$11.87 - $15.96 $20,760 - $27,914	1,749 New	1,749 $22,000

Ticker AKUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,929,000
Description
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.